GSK's stocks have seen various fluctuations due to a range of factors. The stocks' tumble was initially fueled by AnaptysBio's legal fight concerning a cancer drug license. However, a subsequent surge was seen as the CEO exited amid a forecast hike and surprise drug win. The company's strong performance across specialty medicines has granted the full-year outlook a boost. The mixed fortunes continue with JP Morgan lowering GSK's price target while maintaining an underweight rating. The stock gains were reflected in a surge in Q3 pre-tax profit and a revision in the FY25 Growth Outlook. GSK repurchased shares and partnered with LTZ on cancer treatments. However, Warning signs were noted as GSK's narrow approval for a blood cancer drug limited a US relaunch. In a positive development, GSK expanded its Share Buyback program with a recent purchase. The stock value was re-evaluated after shares rose 10% and pharma tariff fears eased in 2025. Overall, GSK's investment story is seen to be shaped by recent developments and considerations for the long term.
GSK Stocks News Analytics from Wed, 21 May 2025 07:00:00 GMT to Fri, 21 Nov 2025 21:46:00 GMT -
Rating 6
- Innovation 2
- Information 8
- Rumor 3
